Unveiling the SOD1 -mediated ALS phenotype: insights from a comprehensive meta-analysis

Background and objectives Amyotrophic lateral sclerosis associated with mutations in SOD1 ( SOD1 -ALS) might be susceptible to specific treatment. The aim of the study is to outline the clinical features of SOD1 -ALS patients by comparing them to patients without ALS major gene variants and patients with variants in other major ALS genes. Defining SOD1 -ALS phenotype may assist clinicians in identifying patients who should be prioritized for genetic testing. Methods We performed an extensive literature research including original studies which reported the clinical features of SOD1 -ALS and at least one of the following patient groups: C9ORF72 hexanucleotide repeat expansion ( C9 -ALS), TARDBP ( TARDBP -ALS), FUS ( FUS -ALS) or patients without a positive test for a major-ALS gene (N-ALS). A random effects meta-analytic model was applied to clinical data extracted encompassing sex, site and age of onset. To reconstruct individual patient survival data, the published Kaplan–Meier curves were digitized. Data were measured as odds ratio (OR) or standardized mean difference (SMD) as appropriate. Median survival was compared between groups. Results Twenty studies met the inclusion criteria. We identified 721 SOD1 -ALS, 470 C9 -ALS, 183 TARDBP -ALS, 113 FUS -ALS and 2824 N-ALS. SOD1 -ALS showed a higher rate of spinal onset compared with N-ALS and C9 -ALS (OR = 4.85, 95% CI = 3.04–7.76; OR = 10.47, 95% CI = 4.32–27.87) and an earlier onset compared with N-ALS (SMD = − 0.45, 95% CI = − 0.72 to − 0.18). SOD1 -ALS had a similar survival compared with N-ALS ( p = 0.14), a longer survival compared with C9 -ALS ( p < 0.01) and FUS -ALS ( p = 0.019) and a shorter survival compared with TARDBP -ALS ( p < 0.01). Discussion This study indicates the presence of a specific SOD1 -ALS phenotype. Insights in SOD1- ALS clinical features are important in genetic counseling, disease prognosis and support patients’ stratification in clinical trials.